NCT00556088 - LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Solid Tumors

Interventions

DRUG

LBH589, Paclitaxel, Carboplatin, Bevacizumab

"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."

Trial Locations (1)

37023

Tennessee Oncology, PLLC, Nashville